Trandolapril (Standard)
Based on 1 Customer Validation
Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.72%
- CAS. Nr.: 87679-37-6
- Formel: C24H34N2O5
- Molecular Weight:430.54
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Reinheit & Dokumentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS. Nr. 87679-37-6
-
Appearance Solid
-
Molecular Weight 430.54
-
Formel C24H34N2O5
-
Color White to off-white
-
SMILES
O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)[C@@]3([H])CCCC[C@]3([H])C1)O
-
Synonyms
RU44570 (Standard)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Peters DC, et al. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 1998 Nov;56(5):871-93. [Content Brief]
[2]. Tan X, et al. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009 Dec;76(12):1248-57. [Content Brief]
[3]. Koffi I, et al. Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 13;361(1):51-60. [Content Brief]
[4]. Chobanian AV, et al. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992 Oct;20(4):473-7. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Trandolapril (Standard) Related Classifications
HY-B0592R Related Classifications
Powered by Bioz
- Trandolapril (Standard)
- 87679-37-6
- RU44570 (Standard)
- Reference Standards
- Angiotensin-converting Enzyme (ACE)
- congestive heart failure
- CHF
- myocardial infarction
- MI
- Trandolaprilat
- orally active
- hypertension
- nonsulfhydryl
- arterial hypertrophy
- collagen
- cellular fibronectin accumulation
- spontaneously hypertensive rats
- UUD model
- unilateral ureteral obstruction
- UUO model
- Inhibitor
- inhibitor
- inhibit